Shares of Aurobindo Pharma rose by over 4 per cent today after the company said it has received final approval from the US health regulator to manufacture Omeprazole delayed-release tablets, used in the treatment of frequent heartburn.
The stock gained 4.42 per cent to settle at Rs 571.95 on BSE. During the day, it jumped 5.43 per cent to Rs 577.50.
At NSE, shares of the company rose by 4.24 per cent to close at Rs 571.
In terms of equity volume, 2.57 lakh shares of the company were traded on BSE and over 39 lakh shares changed hands at NSE during the day.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Omeprazole Delayed-Release tablets OTC, 20mg. The product will be launched in June 2018," Aurobindo Pharma said in a BSE filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app